Clinical trials: Breast Cancer
Metastatic Breast Cancer
Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)
Nab-paclitaxel has demonstrated to be an active agent in breast cancer and probably a less toxic alternative to solvent based taxanes. It is indicated in metastatic breast cancer after failure of anthracyclines.
- Trial name
- NCT01416558
- Testing
- Nab-Paclitaxel
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer
This clinical trial studies ultrasound tomography using SoftVue in diagnosing women with breast cancer. New diagnostic procedures, such as ultrasound tomography using SoftVue, may help find and diagnose breast cancer.
- Trial name
- NCT01698658
- Testing
- ultrasound tomography, magnetic resonance imaging
- Where
- United States
- Volunteers
- 657 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lymphedema of Upper Arm
Responsiveness of Outcome Scales in Breast Cancer Related Lymphedema
The aim of this study is to investigate and compare responsiveness of current lymphedema assessment scales validated in Turkish.
- Trial name
- NCT04138667
- Testing
- complex decongestive therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Marmara University
Breast Cancer
Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer
The purpose of this study is to investigate the safety and imaging ability of 111In-DAC when used with planar and SPECT imaging for the detection of breast cancer.
- Trial name
- NCT00040430
- Testing
- 111In-DAC, Diagnostic
- Where
- 2 sites in United States
- Sponsor
- Copharos
Breast Cancer, Prostate Cancer
Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer
Evaluation of patient reported outcomes (PRO) / QoL regarding typical ailments in real-life patients with bone metastases treated with osteoprotective agents.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Metastases
- Trial name
- PROBone (NCT02410044)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- iOMEDICO AG
Breast Cancer
The Use of Bioimpedance to Determine Pre-Clinical Lymphedema in the Post-Operative Breast Cancer Patient
Primary Objective: To determine whether early intervention (with garment sleeve and gauntlet) in patients with pre-clinical lymphedema can halt the progression of lymphedema.
- Trial name
- L-Dex (NCT01521000)
- Testing
- Garment Sleeve
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Main Line Health
Breast Cancer, Neutropenia
Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
The overall purpose of this study is to assess the dose response, efficacy, and safety of three different dose levels of AVI 014 (granulocyte colony-stimulating factor [G-CSF]) in breast cancer patients at high (>20%) risk for…
- Trial name
- NCT00497809
- Testing
- AVI-014 versus Filgrastim
- Where
- 31 sites in United States, India
- Volunteers
- 189 people
- Sponsor
- AviGenics
Breast Cancer
Comparing the Safety and Cosmetic Outcomes Between Laparoscopic Versus Traditional Open Breast-conserving Surgery
In recent years, laparoscopic breast cancer surgery has received wide attention. It has advantages of minimal invasiveness, clear anatomical exposure, and good aesthetic effects.
- Trial name
- NCT06671249
- Testing
- Laparoscopic breast-conserving surgery, Traditional open breast-conserving surgery
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer, Male Breast Cancer
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with trastuzumab and to see how well they work in treating patients with metastatic breast canceror breast cancer that has…
- Conditions
- Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00258349
- Testing
- vorinostat, trastuzumab
- Where
- 25 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Breast Cancer
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
The primary objective is to evaluate whether Zoladex 10.8 mg (12-weekly) is non-inferior to Zoladex 3.6 mg (4-weekly) in pre-menopausal women with oestrogen receptor positive advanced breast cancer by assessment of…
- Trial name
- NCT00322348
- Testing
- Goserelin acetate
- Where
- 14 sites in Czechia, Russia and 1 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
HER2 Expressing Breast or Gastric/Stomach Cancers
A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.
This research study is designed to evaluate an experimental drug, MEDI4276, in treating breast and stomach (gastric) cancer.
- Trial name
- MEDI4276 (NCT02576548)
- Testing
- MEDI4276
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- MedImmune LLC
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled.
- Conditions
- Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
- Trial name
- BRIDGET (NCT05323955)
- Testing
- Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carey Anders, M.D.
Dietary Assessment, Dietary and Lifestyle Behaviour Change
BRE-13: Mediterranean Diet
Explore the effect of MedDiet vs. Usual Diet on circulating and breast tumor fatty acid profiles. The investigators aim to examine impact on tumor biology in newly diagnosed participants.
- Conditions
- Dietary Assessment, Dietary and Lifestyle Behaviour Change, Dietary Behavior, Metabolic Health
- Trial name
- BRE-13 (NCT07869355)
- Testing
- Explore the effect of MedDiet vs. Usual Diet on Fatty Acid Profile, Explore the effect of MedDiet vs. Usual Diet on Breast Tumor Tissue, Explore the effect of MedDiet vs. Usual Diet on Lipids
- Volunteers
- 30 people
- Sponsor
- University of Illinois at Chicago
Breast Cancer, Surgery
LIMBO : Breast Reconstruction by Lipomodeling Alone or With Flap: Evaluation in Franche-Comté
The Limbo study is a retrospective descriptive study which aims to establish the current state of breast reconstruction surgery at the Besançon University Hospital and Hôpital Nord Franche-Comté, between October 2017 and December…
- Trial name
- LIMBO (NCT06101732)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Breast Cancer
Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill breast cancer cells.
- Trial name
- NCT00004893
- Testing
- recombinant interleukin-12
- Where
- 49 sites in United States
- Volunteers
- 5 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib.
- Trial name
- NCT05966584
- Testing
- Benralizumab, fulvestrant or AIs) and PI3K inhibition (alpelisib)
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Feasibility of Blood Oxygenation Level-Dependent Contrast (BOLD) Breast MRI Induced by Breath- Holding
In this study, investigators intend to measure changes in BOLD contrast in the breast induced by breath-holding for subjects receiving radiation therapy to the breast.
- Trial name
- BOLD (NCT01898533)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Advanced Breast Cancer
Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients
This is a phase II study assessing the activity and safety of metronomic chemotherapy with cyclophosphamide and capecitabine and vinorelbine in advanced breast cancer patient in four different cohort of patients: 1.
- Trial name
- VEX (NCT04304352)
- Testing
- Vinorelbine, Capecitabine, Cyclophosphamide
- Where
- Italy
- Volunteers
- 162 people
- Sponsor
- European Institute of Oncology
Metastatic Breast Cancer, Locally Recurrent Cancer
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
A randomized, multi center, open label, two-period, single dose, crossover study to evaluate the bioavailability and safety of Paclitaxel Injection Concentrate for Suspension in Locally Recurrent or Metastatic Breast Cancer…
- Trial name
- NCT04332549
- Testing
- PICS (Reconstitution Method 1 or 2)
- Where
- 22 sites in India
- Sponsor
- Sun Pharma Advanced Research Company Limited
Advanced or Metastatic Solid Tumors, Breast Cancer
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
- Trial name
- NCT06257758
- Testing
- VIO-01
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Valerio Therapeutics